Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Gary Wittert; Evan Atlantis; Mathis Grossmann; Bu B. Yeap; Ann Conway; Bronwyn Stuckey; David Handelsman; Robert McLachlan; Carolyn Allan; Alicia Jenkins; Mark Daniel; Karen Bracken

Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Gary Wittert
, Evan Atlantis
, Mathis Grossmann
, Bu B. Yeap
, Ann Conway
, Bronwyn Stuckey
, David Handelsman
, Robert McLachlan
, Carolyn Allan
, Alicia Jenkins
, Mark Daniel
, Karen Bracken

Health Research Institute

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

Original language	English
Pages (from-to)	47-48
Number of pages	2
Journal	Clinical Endocrinology
Volume	89
Issue number	S1
Publication status	Published - Jun 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13727

Cite this

Wittert, G., Atlantis, E., Grossmann, M., Yeap, B. B., Conway, A., Stuckey, B., Handelsman, D., McLachlan, R., Allan, C., Jenkins, A., Daniel, M., & Bracken, K. (2018). Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. Clinical Endocrinology, 89(S1), 47-48. https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13727

@article{2373be95ba694f059b9dc4b2506b04d4,

title = "Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial",

abstract = "Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers{\textregistered}) as compared to lifestyle intervention alone, reduces T2D at 2 years.",

author = "Gary Wittert and Evan Atlantis and Mathis Grossmann and Yeap, \{Bu B.\} and Ann Conway and Bronwyn Stuckey and David Handelsman and Robert McLachlan and Carolyn Allan and Alicia Jenkins and Mark Daniel and Karen Bracken",

year = "2018",

month = jun,

language = "English",

volume = "89",

pages = "47--48",

journal = "Clinical Endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell",

number = "S1",

}

Wittert, G, Atlantis, E, Grossmann, M, Yeap, BB, Conway, A, Stuckey, B, Handelsman, D, McLachlan, R, Allan, C, Jenkins, A, Daniel, M & Bracken, K 2018, 'Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial', Clinical Endocrinology, vol. 89, no. S1, pp. 47-48. <https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13727>

TY - JOUR

T1 - Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

AU - Wittert, Gary

AU - Atlantis, Evan

AU - Grossmann, Mathis

AU - Yeap, Bu B.

AU - Conway, Ann

AU - Stuckey, Bronwyn

AU - Handelsman, David

AU - McLachlan, Robert

AU - Allan, Carolyn

AU - Jenkins, Alicia

AU - Daniel, Mark

AU - Bracken, Karen

PY - 2018/6

Y1 - 2018/6

N2 - Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

AB - Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

M3 - Meeting Abstract

SN - 0300-0664

VL - 89

SP - 47

EP - 48

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - S1

ER -

Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this